Press Release

Printer Friendly VersionView printer-friendly version << Back

Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer

SAN FRANCISCO, May 8, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq:BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced the promotion of Natalie Holles from Senior Vice President and Chief Operating Officer to President and Chief Operating Officer.  In this new role, Ms. Holles will oversee the day-to-day operations of the company, including research, development, manufacturing, program management and corporate development. 

"Natalie is a decisive and results-oriented leader who has inspired colleagues across Audentes through a period of rapid growth and the achievement of important corporate milestones," stated Matthew R. Patterson, Chief Executive Officer.  "Today's announcement reflects an evolution in our leadership structure which enables us to continue to scale our organization effectively, achieve our ambitious goals and execute on our mission to bring innovative gene therapy products to patients living with serious, life-threatening rare diseases."

Ms. Holles joined Audentes in 2015, bringing 15 years of corporate development, strategic planning, and commercial experience gained in a range of therapeutic areas and with a focus on rare diseases. Prior to joining Audentes, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010 to 2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. Ms. Holles holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute Predoctoral Fellow, and an A.B. in Human Biology from Stanford University.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases.  We are currently conducting Phase 1/2 clinical studies of our lead product candidates AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) and AT342 for the treatment of Crigler-Najjar Syndrome.  We have two additional product candidates in development, including AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the company's ability to achieve key corporate goals, including but not limited to anticipated clinical milestones, the timing and nature of clinical development activities, the timing of the release of data from ongoing clinical trials, and the timing of regulatory filings.  All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, fund development activities and achieve development goals, establish and scale-up manufacturing processes that comply with regulatory requirements, protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Audentes Contacts:

Investor Contact:
Andrew Chang

Media Contact:
Paul Laland

Audentes Therapeutics, Inc.


Cision View original content with multimedia:

SOURCE Audentes Therapeutics, Inc.